Pulmonary vascular disease & thromboembolismMeta-analysis
Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis
- Systematic review and meta-analysis of randomised trials and cohort studies
- random-effects
- GRADE certainty assessment
Study context
- Population
- Adults with cancer and venous thromboembolism (VTE)
- Participants
- 96,753 adults · 33 studies
- Outcome
- Prognostic factors for recurrent VTE and anticoagulant-related bleeding (pooled adjusted hazard ratios (aHRs))
Pooled result
As reported in the abstract
Recurrent VTE: factors with high certainty of association
Adjusted hazard ratio (95% CI)
Previous history of VTEincreased risk
1.50(1.08–2.09)
ECOG performance status >0increased risk
1.81(1.34–2.46)
ECOG performance status >1increased risk
2.44(1.55–3.84)
Advanced cancerincreased risk
1.38(1.15–1.65)
Lung cancerincreased risk
1.78(1.29–2.46)
Hepatobiliary cancerincreased risk
2.37(1.70–3.30)
Pancreas cancerincreased risk
3.20(2.06–4.96)
Genitourinary cancerincreased risk
1.38(1.14–1.67)
Recent surgerydecreased risk
0.56(0.40–0.76)
Breast cancerdecreased risk
0.43(0.23–0.81)
Further pooled results
Anticoagulant-related bleeding: factors with high certainty of increased risk
| Comparison | aHR (95% CI) | |
|---|---|---|
| History of bleeding | 2.41 (1.50–3.88) | |
| ECOG performance status ≥2 | 2.10 (1.48–2.99) | |
| Advanced cancer | 1.60 (1.29–1.97) | |
| Brain cancer | 2.25 (1.64–3.09) | |
| Gastrointestinal cancer | 1.74 (1.44–2.11) | |
| Genitourinary cancer | 1.90 (1.48–2.45) | |
| Prostate cancer | 1.72 (1.26–2.34) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Original publication
Predictors of recurrent venous thromboembolism and bleeding in patients with cancer: a meta-analysis. Eur Heart J. Published 22 June 2025. doi:10.1093/eurheartj/ehaf453
Summarised from the published abstract; every number is checked against it